Author: Brenda Marie Rivers|| Date Published: July 27, 2020
Moderna has been awarded a potential $472M contract modification by the Biomedical Advanced Research and Development Authority to expand late-stage clinical trials of a messenger RNA-based vaccine candidate for the novel coronavirus.
BARDA’s additional funding commitment increases the potential value of the initial contract to $955M, the company said Sunday.
Under the modification, BARDA pledged funds to support Phase 3 tests of Moderna’s mRNA-1273 vaccine including a study to be conducted with 30K participants.
The biotechnology firm will perform the participant-based trials with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases’ COVID-19 Prevention Trials Network.
“Encouraged by the Phase 1 data, we believe that our mRNA vaccine may aid in addressing the COVID-19 pandemic and preventing future outbreaks,” said Moderna CEO Stephane Bancel.
The company aims to deliver 500M to 1B doses of the potential COVID-19 vaccine starting next year as part of the Trump administration’s Operation Warp Speed.
Client Solution Architects has appointed Ellen Barletto as chief growth officer, expanding her leadership responsibilities after nearly two decades with…
Brian Meyer, federal field chief technology officer at Axonius Federal, said cybersecurity asset management could help government agencies make dozens…
“Technology transformation company Red River has acquired Invictus International Consulting to expand its cybersecurity and enterprise modernization capabilities to support…
Synergy ECP, a software engineering, cybersecurity and systems engineering services provider, has acquired NetServices, a company offering secure, mission-focused technology services. The…
